REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In ...
Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.
The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...
The Department of Pharmacy, Medical Supplies, Equipment, and Supplies, Ministry of Health of Hamad government has warned all ...
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA ® (pembrolizumab) and KEYTRUDA QLEXâ„¢ ...
The case stems from ICIJ’s Cancer Calculus investigation into the world's best-selling drug’s sky-high price and its global ...
FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data. The Food and Drug Administration (FDA) has ...
Regulatory clearance includes IV pembrolizumab and subcutaneous pembrolizumab/berahyaluronidase with belzutifan for adjuvant treatment after nephrectomy, including ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved belzutifan with pembrolizumab as an adjuvant therapy for adults with renal cell carcinoma. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results